From: PR Newswire Doctors can safely lower the dose of cancer treatment such as chemotherapy without impacting survival for adults older than 70 who are at high risk for toxic side effects. The results are from a potentially practice-changing new study, published in The Lancet, and led by a Wilmot Cancer Institute scientist at the University of Rochester Medical Center. …
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
From: businesswire.com Study will evaluate the efficacy and safety of NERLYNX® plus XELODA® in patients selected by the CELsignia® Test who have metastatic HER2-negative breast cancer with brain metastases The unique tumor insights CELsignia generates enable identification of new potential applications for targeted therapies and development of potential first-in-class drugs Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing an …
Scientists light the way for immune system to attack cancer
Source: University of Rochester Medical Center From: sciencedaily.com The science behind harnessing the immune system to fight cancer is complicated, but a University of Rochester Medical Center laboratory discovered a simple, practical way to use light and optics to steer killer immune cells toward tumors. In a study published by the online journal Nature Communications, lead author Minsoo Kim, Ph.D., …